Identification and characterization of a novel linear B-cell epitope on nucleocapsid protein of porcine epidemic diarrhea virus Authors: Jingwen Wang, Weiqiang Zhang, Hao Lu, Chenlin Hao, Nianxiang Wang, Ziqi Wang, Erhao Zhang, Shichong Han, Lu Xia, Hui Hu Published: 2025 ABSTRACT BackgroundPorcine epidemic diarrhea virus (PEDV) is a highly virulent enterovirus that is responsible for severe diarrhea in neonatal piglets. For no effective vaccine or specific treatment are available, rapid and accurate diagnosis is crucial for the prevention and control of disease. The nucleocapsid (N) protein is conserved with strong immunogenicity, making it an important target for developing serological approaches.ResultsIn this study, soluble PEDV N protein was expressed, purified, and then used to produce monoclonal antibodies (mAbs). Three mAbs, named 8G2, 6F3, and 3E1, against PEDV N protein were generated. These mAbs were identified as IgG1 isotypes with κ light chains, exhibited high specificity for PEDV, and showed no cross-reactivity with transmissible gastroenteritis virus (TGEV) or porcine deltacoronavirus (PDCoV). Epitope mapping revealed 8G2 specifically recognized a novel linear B-cell epitope at 274-DLKDIPEWR-282 of viral N protein by using a serious of truncated overlapping peptides. Homology analysis showed that the epitope of 8G2 was highly conserved (100%) among different PEDV strains. Structural assay suggested that the identified epitope was located on the surface of PEDV N protein. Functional analysis demonstrated 8G2 could be used in indirect immunofluorescence assay, western blot, flow cytometry, and immunohistochemistry.ConclusionsThese mAbs help us better understanding the antigenicity of PEDV N protein, and serve as robust tools for serological diagnosis and vaccine development.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12917-025-05221-w. Background Porcine epidemic diarrhea is an acute enteric disease caused by porcine epidemic diarrhea virus (PEDV), characterized by vomiting, diarrhea, and dehydration. PEDV can infect pigs of all ages, and the morbidity and mortality of piglets within 7 days old can reach 100% [1, 2]. PEDV was first identified in England in 1971 and named as CV777. Since 2010, highly pathogenic PEDV variant strains have rapidly spread around the world and caused great economic losses to the pig industry [3, 4]. PEDV is an enveloped, single-stranded, positive-sense RNA virus, which belongs to the order Nidovirales, family Coronaviridae, and genus Alphacoronavirus. The whole genome of PEDV is about 28 kb, including a 5’ untranslated region (UTR), open reading frame (ORF) 1a/1b, spike (S) protein, ORF3 accessory protein, envelope (E) protein, membrane (M) protein, nucleocapsid (N) protein, and 3’ UTR [5, 6]. As coronavirus carry the largest genomes among known RNA viruses, their complex structures and immunological characteristics remain poorly understood [7]. As the most abundant protein in virions, N protein has multiple functions in viral life cycle and pathogenesis. N protein is responsible for packaging viral RNA genome to form ribonucleoprotein structures preventing degradation [8, 9]. N protein also participates in the establishment of viral replication-transcriptional complex and interacts with other structural proteins, facilitating viral replication and assembly [6, 10]. On the hand of host-pathogen interactions, N protein plays important roles in regulating host cell cycle progression, apoptosis, and cell stress responses [11]. Notably, N protein is highly stable, conserved, and has strong immunogenicity that induce protective immune responses. Due to these features, it is an ideal target for the development of vaccines and diagnostics methods. Monoclonal antibodies (mAbs) are essential tools for understanding disease pathogenesis and protein function, targeted therapies, and are used in diagnostic research to identify disease markers [12]. Therefore, characterizing mAbs against PEDV N protein and their corresponding epitopes is crucial. Although several studies have identified the PEDV N protein, information on the number and location of its most immunogenic epitopes remains limited [13–15]. Further research is needed to fully characterize these epitopes for diagnostic and potential vaccine development. In this study, PEDV N protein were expressed in E. coli, purified, and then used to immunize mice for mAb production. Three mAbs (8G2, 6F3, and 3E1) were generated, and their antibody titer, subtypes, reactivity and specificity were then verified. Due to mAb 8G2 exhibited the highest affinity and specifically reacted with PEDV N protein in the immunofluorescence assay (IFA), we further identified its epitopes, evaluated its conservation among different PEDV strains, and explored its preliminary applications. These mAbs lay a foundation for further investigation of the biological function of PEDV N protein, as well as developing practical applications to PEDV. Methods Cells, virus, and animals Vero cells, swine testicular (ST) cells, and myeloma cell line SP2/0 cells were preserved in our laboratory. Vero cells and ST cells were cultured in Dulbecco’s modified eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) under a humidified atmosphere at 37 °C with 5% CO2. SP2/0 cells were grown in serum-free medium. PEDV CV777 (Genbank: AF353511.1) strain, transmissible gastroenteritis virus (TGEV) HN-2012 (Genbank: OP434397.1) strain, and porcine deltacoronavirus (PDCoV) HNZK-02 (Genbank: MH708123) strain were preserved by our laboratory. 6–8 weeks old female BALB/c mice were purchased from Henan Laboratory Animal Center (Zhengzhou, China). Mice were housed in the Animal Experimental Center of Henan Agricultural University, and were handled in accordance with the National Standard for Laboratory Animals. Gene cloning, expression, and purification of recombinant PEDV N protein PEDV N gene was amplified from the cDNA of PEDV by polymerase chain reaction (PCR). Primers were designed using the homologous recombination method and are listed in Table 1. Target fragments were inserted into pET-32a (+) vector. The recombinant pET-32a-PEDV N plasmid were verified by EcoR I and Hind ⅠⅠⅠ restriction enzyme digestion. Then pET-32a-PEDV N were transformed into E.coli Rosetta(DE3)cells (Vazyme). The transformed cells were cultured in Luria-Bertani (LB) medium and induced with 0.7 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 37 °C until the optical density at 600 nm (OD600 nm) reached 0.6 ~ 0.8. Entire bacteria cells were collected, resuspended in PBS, lysed by sonication, and centrifuged at 8000 rpm for 10 min. For purification, the supernatant containing recombinant protein was combined with Ni-NTA agarose column (Sangon Biotech) for 2 h, and the bound was then eluted with different concentrations of Imidazole. Protein was evaluated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and western blot (WB). Table 1Primers for PEDV NPrimerSequence (5’–3’)Size (bp)PEDV NF: ATCGGATCCGAATTCGCTTCTGTCAGCTTTCA1320R: TGCGGCCGCAAGCTTATTTCCTGTGTCGAAGA Table 1Primers for PEDV NPrimerSequence (5’–3’)Size (bp)PEDV NF: ATCGGATCCGAATTCGCTTCTGTCAGCTTTCA1320R: TGCGGCCGCAAGCTTATTTCCTGTGTCGAAGA Primers for PEDV N Production of mAbs against PEDV N protein Purified PEDV N protein was mixed 1:1 with Freund’s adjuvant (complete for the first immunization, incomplete thereafter), and used to immunize mice three times at 14-day intervals. Control mice and immunized mice were raised separately under identical environmental conditions. Serum samples from tail vein in mice were collected, and antibodies against PEDV N protein were measured by an indirect enzyme-linked immunosorbent assay (ELISA). Immunized mice with the highest antibody titer were given a booster immunization for three days. Then the mice were euthanized by intraperitoneal injection of sodium pentobarbital (100 mg/kg body weight), which complies with guidelines of the American Veterinary Medical Association (AVMA) for the Euthanasia of Animals (2020). Spleen cells were immediately collected and fused with SP2/0 myeloma cells using polyethylene glycol 1420 (Sigma). Fused cells were seeded in 96-well plates and cultured in hybridoma medium containing hypoxanthine-aminopterin-thymidine (HAT, Sigma) for seven days and then replaced with hypoxanthine-thymidine (HT, Sigma). Positive cell clones were screened by indirect ELISA, and then subcloned by the limiting dilution method for at least three rounds. Monoclonal hybridoma cells were cultured and injected intraperitoneally into mice to stimulate the formation of ascites. After one week, ascites was collected, and the antibodies were purified using the caprylic acid-ammonium sulfate precipitation method. The titers of purified mAbs were determined by indirect ELISA. The subtypes of mAbs were identified using a Mouse Monoclonal Antibody Subtype Identification Kit (Proteintech). Indirect ELISA ELISA plates were coated with 100 µL of recombinant PEDV N protein (1 µg/mL) in bicarbonate buffer and incubated at 4℃ overnight. Phosphate buffer saline (PBS) was used as a negative control in place of antigen. After four PBST (PBS containing 0.05% Tween 20) washes, plates were blocked with 1.5% bovine serum albumin (BSA, Sigma) at 37℃ for 1 h. Then, 100 µL of the primary antibody was added to each well and incubated at 37℃ for 1 h. Plates were washed with PBST again, and horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1:8000, Proteintech) were used as secondary antibodies incubating for 1 h at 37℃. Subsequently, 100 µL of TMB substrate were added and reacted at 37℃ for 10 min. The reaction was stopped by adding 50 µL of 2 M H2SO4. Values were read at OD450 nm using a microplate reader. Eukaryotic expression of PEDV N protein PEDV N gene was cloned into the eukaryotic expression vector pCAGGS-HA. The specific primers are F: 5’-TACGATGTTCCAGATTA CGCTGAATTCATGGCTTCTGTCAGC-3’, R: 5’-TAATTAAGATCTGC TAGCTCGAGATTTCCTGTGTCGAAGA-3’. Recombinant pCAGGS-HA-PEDV N was sequenced, and then transfected into Vero cells with Lipofectamine 3000 Reagent (Invitrogen) according to the manufacturer’s instructions. After 24 h transfection, cells were collected for subsequent detection. IFA Monolayer Vero cells or ST cells were infected TGEV, PEDV or PDCoV at a multiplicity of infection (MOI) of 1. In parallel, Vero cells were transfected with pCAGGS-HA-PEDV N or organelle marker plamids (pDsRed2-Mito, pDsRed2-ER, pDsRed-Monomer-Golgi, pDsRed2-LAMP1 and pDsRed2-Peroxi), respectively. At the indicated time points, cells were washed with PBS, fixed with 4% paraformaldehyde at 4°C for 15 min, permeabilized with 0.5% Triton X-100 at room temperature for 10 min, and blocked with 5% BSA at 37°C for 1 h. After primary antibody incubation at 4°C overnight, cells were washed five times with PBS. Then cells were treated with anti-Mouse IgG (whole molecule) Atto 488 antibody (Proteintech) at 37°C for 1 h. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, 1:1000). Images were acquired by fluorescence microscope (ZEISS). SDS-PAGE and WB analysis Cellular proteins were extracted by lysis buffer, mixed with 6 × loading buffer, and boiled for 10 min. Total proteins were separated by 10% SDS-PAGE and stained with Coomassie brilliant blue. For WB, separated proteins were transferred to NC membranes and blocked with 5% non-fat milk at room temperature for 2 h. Then NC membranes were incubated with primary antibodies at 4 °C overnight. After five washes with TBST, NC membranes were incubated with suitable secondary antibodies for 2 h. Proteins were visualized using an enhanced chemiluminescence reagent (Beyotime), and imaged using an AmershamImager800 system. Identification of the epitope of mAb 8G2 To identify the minimal B-cell epitope recognized by mAb 8G2, PEDV N protein was progressively truncated in four rounds, generating a series of overlapping fragments or polypeptides. The primers of truncated fragments in round 1 and round 2 were designed as described previously and are shown in Tables 2 and 3, respectively. Primers for the shorter fragments (round 3 and round 4) were designed according to the touch down PCR principle (Tables 4 and 5). The correct cDNAs of truncated fragments were subcloned into pET-32a vector and expressed in DE3 cells. The molecular weight and reactivity of these truncations were analyzed by SDS-PAGE and WB, respectively. To identify the critical amino acids in the 274–282 epitope, each amino acid residue was sequentially substituted with alanine (Table 5). Mutant proteins were expressed in DE3, and their reactivity was determined by WB. Table 2Primers for PEDV N truncated proteinTruncated proteinSequence (5’-3’)Positions (aa)N1F: gctgatatcggatccgaattcATGGCTTCTGTCAGCTTTCAGG1-147R: ctcgagtgcggccgcaagcttCGAATTTGTACGTGAAGCAGGAN2F: gctgatatcggatccgaattcAAGCCAATTATTCCAAAATTCTCTC118–325R: ctcgagtgcggccgcaagcttCAAACTGGCGATCTGAGCATAGN3F: gctgatatcggatccgaattcGGACCCAGGGGGGGCTTC296–442R: ctcgagtgcggccgcaagcttTTAATTTCCTGTGTCGAAGATCTCG Table 2Primers for PEDV N truncated proteinTruncated proteinSequence (5’-3’)Positions (aa)N1F: gctgatatcggatccgaattcATGGCTTCTGTCAGCTTTCAGG1-147R: ctcgagtgcggccgcaagcttCGAATTTGTACGTGAAGCAGGAN2F: gctgatatcggatccgaattcAAGCCAATTATTCCAAAATTCTCTC118–325R: ctcgagtgcggccgcaagcttCAAACTGGCGATCTGAGCATAGN3F: gctgatatcggatccgaattcGGACCCAGGGGGGGCTTC296–442R: ctcgagtgcggccgcaagcttTTAATTTCCTGTGTCGAAGATCTCG Primers for PEDV N truncated protein Table 3Primers for PEDV N2 truncated proteinTruncated proteinSequence (5’-3’)Positions (aa)N2-1F: ATGGCTGATATCGGATCCGAATTCaacacacctcctgct138–175R: GTGCTCGAGTGCGGCCGCAAGCTTtgaattaccacgggactggN2-2F: ATGGCTGATATCGGATCCGAATTCagaggcaacaaccagtcc166–203R: GTGCTCGAGTGCGGCCGCAAGCTTCTGGTTACGAGACTTN2-3F: GGCCATGGCTGATATCGGATCCGAATTCaataataacaataac194–231R: GTGGTGCTCGAGTGCGGCCGCAAGCTTtttaagggcatccttN2-4F: ATGGCTGATATCGGATCCGAATTCctggtggctgctgtc222–259R: GGTGCTCGAGTGCGGCCGCAAGCTTattttttccgctgttN2-5F: ATGGCTGATATCGGATCCGAATTCcaggaaaagtctgac250–287R: GTGCTCGAGTGCGGCCGCAAGCTTgcccttgggaattctN2-6F: ATGGCTGATATCGGATCCGAATTCatcccagagtggagga278–325R: GGTGCTCGAGTGCGGCCGCAAGCTTcaaactggcgatctga Table 3Primers for PEDV N2 truncated proteinTruncated proteinSequence (5’-3’)Positions (aa)N2-1F: ATGGCTGATATCGGATCCGAATTCaacacacctcctgct138–175R: GTGCTCGAGTGCGGCCGCAAGCTTtgaattaccacgggactggN2-2F: ATGGCTGATATCGGATCCGAATTCagaggcaacaaccagtcc166–203R: GTGCTCGAGTGCGGCCGCAAGCTTCTGGTTACGAGACTTN2-3F: GGCCATGGCTGATATCGGATCCGAATTCaataataacaataac194–231R: GTGGTGCTCGAGTGCGGCCGCAAGCTTtttaagggcatccttN2-4F: ATGGCTGATATCGGATCCGAATTCctggtggctgctgtc222–259R: GGTGCTCGAGTGCGGCCGCAAGCTTattttttccgctgttN2-5F: ATGGCTGATATCGGATCCGAATTCcaggaaaagtctgac250–287R: GTGCTCGAGTGCGGCCGCAAGCTTgcccttgggaattctN2-6F: ATGGCTGATATCGGATCCGAATTCatcccagagtggagga278–325R: GGTGCTCGAGTGCGGCCGCAAGCTTcaaactggcgatctga Primers for PEDV N2 truncated protein Table 4Primers for PEDV N2-5 truncated proteinTruncated proteinSequence (5’-3’)Positions (aa)N2-5-1F: AATTCaacagcggaaaaaatacacctaagaagaacaaatccA255–266R: AGCTTggatttgttcttcttaggtgtattttttccgctgttGN2-5-2F: AATTCagcggaaaaaatacacctaagaagaacaaatccaggA256–267R: AGCTTcctggatttgttcttcttaggtgtattttttccgctGN2-5-3F: AATTCggaaaaaatacacctaagaagaacaaatccagggccA257–268R: AGCTTggccctggatttgttcttcttaggtgtattttttccGN2-5-4F: AATTCaaaaatacacctaagaagaacaaatccagggccactA258–269R: AGCTTagtggccctggatttgttcttcttaggtgtatttttGN2-5-5F: AATTCaatacacctaagaagaacaaatccagggccacttcgA259–270R: AGCTTcgaagtggccctggatttgttcttcttaggtgtattGN2-5-6F: AATTCacacctaagaagaacaaatccagggccacttcgaagA260–271R: AGCTTcttcgaagtggccctggatttgttcttcttaggtgtGN2-5-7F: AATTCcctaagaagaacaaatccagggccacttcgaaggaaA261–272R: AGCTTttccttcgaagtggccctggatttgttcttcttaggGN2-5-8F: AATTCaagaagaacaaatccagggccacttcgaaggaacgtA262–273R: AGCTTacgttccttcgaagtggccctggatttgttcttcttGN2-5-9F: AATTCaagaacaaatccagggccacttcgaaggaacgtgacA263–274R: AGCTTgtcacgttccttcgaagtggccctggatttgttcttGN2-5-10F: AATTCaacaaatccagggccacttcgaaggaacgtgacctcA264–275R: AGCTTgaggtcacgttccttcgaagtggccctggatttgttGN2-5-11F: AATTCaaatccagggccacttcgaaggaacgtgacctcaaaA265–276R: AGCTTtttgaggtcacgttccttcgaagtggccctggatttGN2-5-12F: AATTCtccagggccacttcgaaggaacgtgacctcaaagacA266–277R: AGCTTgtctttgaggtcacgttccttcgaagtggccctggaGN2-5-13F: AATTCagggccacttcgaaggaacgtgacctcaaagacatcA267–278R: AGCTTgatgtctttgaggtcacgttccttcgaagtggccctGN2-5-14F: AATTCgccacttcgaaggaacgtgacctcaaagacatcccaA268–279R: AGCTTtgggatgtctttgaggtcacgttccttcgaagtggcGN2-5-15F: AATTCacttcgaaggaacgtgacctcaaagacatcccagagA269–280R: AGCTTctctgggatgtctttgaggtcacgttccttcgaagtGN2-5-16F: AATTCtcgaaggaacgtgacctcaaagacatcccagagtggA270–281R: AGCTTccactctgggatgtctttgaggtcacgttccttcgaGN2-5-17F: AATTCaaggaacgtgacctcaaagacatcccagagtggaggA271–282R: AGCTTcctccactctgggatgtctttgaggtcacgttccttGN2-5-17-1F: AATTCgaacgtgacctcaaagacatcccagagtggaggA272–282R: AGCTTcctccactctgggatgtctttgaggtcacgttcGN2-5-17-2F: AATTCcgtgacctcaaagacatcccagagtggaggA273–282R: AGCTTcctccactctgggatgtctttgaggtcacgGN2-5-17-3F: AATTCgacctcaaagacatcccagagtggaggA274–282R: AGCTTcctccactctgggatgtctttgaggtcGN2-5-17-4F: AATTCctcaaagacatcccagagtggaggA275–282R: AGCTTcctccactctgggatgtctttgagGN2-5-17-5F: AATTCaaagacatcccagagtggaggA276–282R: AGCTTcctccactctgggatgtctttG Table 4Primers for PEDV N2-5 truncated proteinTruncated proteinSequence (5’-3’)Positions (aa)N2-5-1F: AATTCaacagcggaaaaaatacacctaagaagaacaaatccA255–266R: AGCTTggatttgttcttcttaggtgtattttttccgctgttGN2-5-2F: AATTCagcggaaaaaatacacctaagaagaacaaatccaggA256–267R: AGCTTcctggatttgttcttcttaggtgtattttttccgctGN2-5-3F: AATTCggaaaaaatacacctaagaagaacaaatccagggccA257–268R: AGCTTggccctggatttgttcttcttaggtgtattttttccGN2-5-4F: AATTCaaaaatacacctaagaagaacaaatccagggccactA258–269R: AGCTTagtggccctggatttgttcttcttaggtgtatttttGN2-5-5F: AATTCaatacacctaagaagaacaaatccagggccacttcgA259–270R: AGCTTcgaagtggccctggatttgttcttcttaggtgtattGN2-5-6F: AATTCacacctaagaagaacaaatccagggccacttcgaagA260–271R: AGCTTcttcgaagtggccctggatttgttcttcttaggtgtGN2-5-7F: AATTCcctaagaagaacaaatccagggccacttcgaaggaaA261–272R: AGCTTttccttcgaagtggccctggatttgttcttcttaggGN2-5-8F: AATTCaagaagaacaaatccagggccacttcgaaggaacgtA262–273R: AGCTTacgttccttcgaagtggccctggatttgttcttcttGN2-5-9F: AATTCaagaacaaatccagggccacttcgaaggaacgtgacA263–274R: AGCTTgtcacgttccttcgaagtggccctggatttgttcttGN2-5-10F: AATTCaacaaatccagggccacttcgaaggaacgtgacctcA264–275R: AGCTTgaggtcacgttccttcgaagtggccctggatttgttGN2-5-11F: AATTCaaatccagggccacttcgaaggaacgtgacctcaaaA265–276R: AGCTTtttgaggtcacgttccttcgaagtggccctggatttGN2-5-12F: AATTCtccagggccacttcgaaggaacgtgacctcaaagacA266–277R: AGCTTgtctttgaggtcacgttccttcgaagtggccctggaGN2-5-13F: AATTCagggccacttcgaaggaacgtgacctcaaagacatcA267–278R: AGCTTgatgtctttgaggtcacgttccttcgaagtggccctGN2-5-14F: AATTCgccacttcgaaggaacgtgacctcaaagacatcccaA268–279R: AGCTTtgggatgtctttgaggtcacgttccttcgaagtggcGN2-5-15F: AATTCacttcgaaggaacgtgacctcaaagacatcccagagA269–280R: AGCTTctctgggatgtctttgaggtcacgttccttcgaagtGN2-5-16F: AATTCtcgaaggaacgtgacctcaaagacatcccagagtggA270–281R: AGCTTccactctgggatgtctttgaggtcacgttccttcgaGN2-5-17F: AATTCaaggaacgtgacctcaaagacatcccagagtggaggA271–282R: AGCTTcctccactctgggatgtctttgaggtcacgttccttGN2-5-17-1F: AATTCgaacgtgacctcaaagacatcccagagtggaggA272–282R: AGCTTcctccactctgggatgtctttgaggtcacgttcGN2-5-17-2F: AATTCcgtgacctcaaagacatcccagagtggaggA273–282R: AGCTTcctccactctgggatgtctttgaggtcacgGN2-5-17-3F: AATTCgacctcaaagacatcccagagtggaggA274–282R: AGCTTcctccactctgggatgtctttgaggtcGN2-5-17-4F: AATTCctcaaagacatcccagagtggaggA275–282R: AGCTTcctccactctgggatgtctttgagGN2-5-17-5F: AATTCaaagacatcccagagtggaggA276–282R: AGCTTcctccactctgggatgtctttG Primers for PEDV N2-5 truncated protein Table 5Primers for site-directed mutagenesisPrimerSequence (5’-3’)275-Lf: AATTCgacgccaaagacatcccagagtggaggAr: AGCTTcctccactctgggatgtctttggcgtcG276-Kf: AATTCgacctcgccgacatcccagagtggaggAr: AGCTTcctccactctgggatgtcggcgaggtcG277-Df: AATTCgacctcaaagccatcccagagtggaggAr: AGCTTcctccactctgggatggctttgaggtcG278-If: AATTCgacctcaaagacgccccagagtggaggAr: AGCTTcctccactctggggcgtctttgaggtcG279-Pf: AATTCgacctcaaagacatcgccgagtggaggAr: AGCTTcctccactcggcgatgtctttgaggtcG280-Ef: AATTCgacctcaaagacatcccaGCCtggaggAr: AGCTTcctccaGGCtgggatgtctttgaggtcG281-Wf: AATTCgacctcaaagacatcccagagGCCaggAr: AGCTTcctGGCctctgggatgtctttgaggtcG Table 5Primers for site-directed mutagenesisPrimerSequence (5’-3’)275-Lf: AATTCgacgccaaagacatcccagagtggaggAr: AGCTTcctccactctgggatgtctttggcgtcG276-Kf: AATTCgacctcgccgacatcccagagtggaggAr: AGCTTcctccactctgggatgtcggcgaggtcG277-Df: AATTCgacctcaaagccatcccagagtggaggAr: AGCTTcctccactctgggatggctttgaggtcG278-If: AATTCgacctcaaagacgccccagagtggaggAr: AGCTTcctccactctggggcgtctttgaggtcG279-Pf: AATTCgacctcaaagacatcgccgagtggaggAr: AGCTTcctccactcggcgatgtctttgaggtcG280-Ef: AATTCgacctcaaagacatcccaGCCtggaggAr: AGCTTcctccaGGCtgggatgtctttgaggtcG281-Wf: AATTCgacctcaaagacatcccagagGCCaggAr: AGCTTcctGGCctctgggatgtctttgaggtcG Primers for site-directed mutagenesis Analysis of the homology of epitope To analyze whether the 8G2 epitope was conserved, the sequences of N protein from other PEDV strains, as well as from different subgroups of coronaviruses, were downloaded from NCBI. Sequence alignment among these coronaviruses were conducted by DNAMAN software. Data were processed using the R programming language. Structural analysis The structural features of PEDV N protein were predicted. DNASTAR software was used to analyze the secondary structures of PEDV N protein. Three-dimensional structure was carried out by AlphaFold3 to determine the exact location of the mAb 8G2 epitope. Flow cytometry analysis The infection rate of PEDV in Vero cells were explored by flow cytometry. Vero cells were infected with PEDV at an MOI of 1 and harvested at different times post infection. Vero cells were dissociated with EDTA-free trypsin to generate single-cell suspensions. After fixation and permeabilization with Fixation/Permeabilization solution (BD), cells were stained with mAb 8G2 at 4 °C for 30 min. After three washes, cells were incubated with DyLight 488-conjugated goat anti-mouse IgG (Proteintech) at 37 °C for 50 min. Finally, cells were resuspended in 300 µL PBS, filtered through a 70-µm cell strainer, and analyzed by BD FACSLyric flow cytometer. Immunohistochemistry (IHC) staining Jejunal tissue sections from TGEV, PEDV, or PDCoV infected piglets were fixed with 4% paraformaldehyde, dehydrated, embedded in paraffin, and sectioned. Slides were dewaxed and hydrated, and antigen repair was performed with 0.01 M sodium citrate buffer solution. Hydrogen peroxide solution was used to block the interference of endogenous peroxidase, and BSA was used to block non-specific binding. The slides were incubated with MAb 8G2 at 4 °C overnight. Then Biotin-labeled goat anti-Mouse IgG polymer and streptomycin antibiotic protein-peroxidase were incubated at room temperature for 10 min, respectively. Tissue sections were colored with the AEC chromogenic kit. Images were scanned by automatic biological microscope. Statistical analysis Results are expressed as the means ± standard. All data were analyzed by one-way ANOVA in GraphPad Prism 6 software. Differences were considered significant at * 0.01 < p < 0.05, ** p < 0.01. Results Expression, purification, and analysis of PEDV N protein Full-length PEDV N genes were successfully amplified and cloned into the prokaryotic expression vector pET-32a. Positive clones were selected, and gene sequencing confirmed PEDV N gene is 1320 bp long and encodes a 440-amino acid protein (Fig. 1A). The correctly identified sequence was then successfully cloned into the prokaryotic expression vector pET-32a (Fig. 1B). Recombined pET-32a-PEDV N plasmid was transformed into DE3 cells, and whole proteins were extracted by lysing bacteria. SDS-PAGE showed the molecular weight of recombinant PEDV N protein is approximately 70 kDa, and it was expressed mainly as soluble form in the supernatant of the bacterial lysate (Fig. 1C). Recombinant proteins were subsequently purified with Ni-TED Sepharose Fast Flow. PEDV N protein bound to Ni-NTA agarose was eluted with 100 mM Imidazole (Fig. 1D). Then the purified protein was confirmed with PEDV-positive serum, which were purchased from the China Institute of Veterinary Drug Control. Recombinant PEDV N protein exhibited strong reactivity with positive serum and anti-His antibody, and specific band appeared at 70 kDa (Fig. 1E and 1F). These results indicated recombinant PEDV N protein was successfully expressed, purified, and suitable for the following experiments. Fig. 1Expression and purification of recombinant PEDV N protein. A Amplification of PEDV N gene. Lane M, 2000 bp DNA marker; lane 1, negative control; lane 2, PEDV N gene. B The plasmid of recombined pET-32a-PEDV N was extracted and identified by PCR amplification. Lane M, 2000 bp DNA marker; lane 1, negative control; lane 2: positive control; lane 3–5, plasmid from randomly selected E. coli colony. C The prokaryotic expression of PEDV N protein were separated by SDS-PAGE and stained with Coomassie brilliant blue. Lane M, 180 kDa molecular weight marker; lane 1, DE3 containing pET-32a vector after induction by IPTG; lane 2, whole cell lysate of DE3 containing pET-32a-PEDV N; line 3, supernatant of DE3 containing pET-32a-PEDV N; line 4, pellet DE3 containing pET-32a-PEDV N. D The purification of PEDV N protein. Lane M, 180 kDa molecular weight marker; lane 1, DE3 containing pET-32a vector after induction; Lane 2, 3, and 4: whole cell lysate, supernatant, and pellet from DE3 containing pET-32a-PEDV N; Lane 5, Flow through; Lane 6–7: 10 mM Imidazole elution; Lane 8–9: 20 mM Imidazole elution; Lane 10–11: 100 mM Imidazole elution; Lane 12–13: 500 mM Imidazole elution. E and F The expression of recombinant PEDV N protein was confirmed using either positive serum (E) or anti-His antibody (F). Lane M, 180 kDa molecular weight marker; lane 1, purified PEDV N protein; lane 2, pET-32a vector as the negative control Expression and purification of recombinant PEDV N protein. A Amplification of PEDV N gene. Lane M, 2000 bp DNA marker; lane 1, negative control; lane 2, PEDV N gene. B The plasmid of recombined pET-32a-PEDV N was extracted and identified by PCR amplification. Lane M, 2000 bp DNA marker; lane 1, negative control; lane 2: positive control; lane 3–5, plasmid from randomly selected E. coli colony. C The prokaryotic expression of PEDV N protein were separated by SDS-PAGE and stained with Coomassie brilliant blue. Lane M, 180 kDa molecular weight marker; lane 1, DE3 containing pET-32a vector after induction by IPTG; lane 2, whole cell lysate of DE3 containing pET-32a-PEDV N; line 3, supernatant of DE3 containing pET-32a-PEDV N; line 4, pellet DE3 containing pET-32a-PEDV N. D The purification of PEDV N protein. Lane M, 180 kDa molecular weight marker; lane 1, DE3 containing pET-32a vector after induction; Lane 2, 3, and 4: whole cell lysate, supernatant, and pellet from DE3 containing pET-32a-PEDV N; Lane 5, Flow through; Lane 6–7: 10 mM Imidazole elution; Lane 8–9: 20 mM Imidazole elution; Lane 10–11: 100 mM Imidazole elution; Lane 12–13: 500 mM Imidazole elution. E and F The expression of recombinant PEDV N protein was confirmed using either positive serum (E) or anti-His antibody (F). Lane M, 180 kDa molecular weight marker; lane 1, purified PEDV N protein; lane 2, pET-32a vector as the negative control Production and characterization of mAbs against PEDV N protein BALB/c mice were immunized with recombinant PEDV N protein to generate specific mAbs. Mice were subcutaneously injected with PEDV N protein (60 µg per mouse) once every two weeks. Ten days after the third immunization, indirect ELISA showed the antibody titers of the immunized mice reached 1:12800 (Fig. 2A). Mouse 1 with the highest antibody titer was sacrificed, and spleen cells were fused with SP2/0 cells. The supernatant of the hybridoma cell cultures were analyzed by indirect ELISA and IFA to screen for antibody-secreting cells. After three rounds of limited dilution subcloning, three positive hybridoma cell lines, namely 8G2 ,6F3, and 3E1, were acquired. Indirect ELISA showed three mAbs had much higher reactivity to the N protein than the negative control SP2/0 cells supernatant did (Fig. 2B). These hybridoma cells were subsequently injected into the peritoneal cavity of mice to produce mAbs. The mAbs were purified from ascites, and their subtypes were characterized by the mouse monoclonal antibody subtype identification kit. The heavy chains of three screened mAbs were IgG1, and the light chains were kappa type (Fig. 2C). The titers of these mAbs reached as high as 1:102400 (Fig. 2D). Fig. 2Preparation and identification of mAbs against PEDV N protein. A BALB/c mice were immunized with purified PEDV N protein, and antibody titers in tail sera of mice were detected by indirect ELISA. B Splenocytes from immunized mice were fused with SP2/0 cell, and the reactivity of three positive clones (8G2, 6F3, and 3E1) with PEDV N protein were analyzed by indirect ELISA. C The isotype of mAbs were identified by ELISA, and SP2/0 cell supernatant was used as a negative control. D The titers of purified mAbs were detected by ELISA Preparation and identification of mAbs against PEDV N protein. A BALB/c mice were immunized with purified PEDV N protein, and antibody titers in tail sera of mice were detected by indirect ELISA. B Splenocytes from immunized mice were fused with SP2/0 cell, and the reactivity of three positive clones (8G2, 6F3, and 3E1) with PEDV N protein were analyzed by indirect ELISA. C The isotype of mAbs were identified by ELISA, and SP2/0 cell supernatant was used as a negative control. D The titers of purified mAbs were detected by ELISA Reactivity and specificity of screened mAbs against PEDV The reactivity and specificity of three mAbs were evaluated. 8G2, 6F3, and 3E1 reacted with N protein from PEDV-infected cells, as well as in Vero cells transfected with pCAGGS-HA-PEDV N plasmid (Fig. 3A). Green fluorescence was observed in PEDV-infected Vero cells stained with mAb 8G2, whereas no fluorescence was observed in cells incubated with mAb 6F3 or 3E1, nor in mock infected cells (Fig. 3B). WB and indirect ELISA confirmed that these mAbs specifically recognized PEDV, with no reactivity observed against with PDCoV or TGEV strains in our study (Fig. 3C and D). Additionally, Fig. 3E further demonstrated that mAb 8G2 specifically reacted with PEDV. These results suggested that the mAbs prepared in this study recognize native PEDV N protein, and have no cross-reaction with TGEV or PDCoV. Fig. 3Reactivity and specificity of mAbs against PEDV N protein. A Vero cells were infected with PEDV or transfected with pCAGGS-HA-PEDV N, and the reactivity of mAbs against PEDV or PEDV N protein were analyzed by WB. B Vero cells were infected with PEDV, and then cells were fixed for IFA. C and D The specificity of mAbs against TGEV, PEDV, and PDCoV were deteced by WB (C) and indirect ELISA (D), respectively. E Cells were infected with PEDV, TGEV, or PDCoV, and then fixed and stained with mAb 8G2 Reactivity and specificity of mAbs against PEDV N protein. A Vero cells were infected with PEDV or transfected with pCAGGS-HA-PEDV N, and the reactivity of mAbs against PEDV or PEDV N protein were analyzed by WB. B Vero cells were infected with PEDV, and then cells were fixed for IFA. C and D The specificity of mAbs against TGEV, PEDV, and PDCoV were deteced by WB (C) and indirect ELISA (D), respectively. E Cells were infected with PEDV, TGEV, or PDCoV, and then fixed and stained with mAb 8G2 Mapping the epitope of mAb 8G2 As mAb 8G2 had the highest titer and was the sole antibody capable of IFA, the epitope of 8G2 were identified in subsequent experiments. A series of truncated proteins were designed and expressed according to the schematic diagram (Fig. 4A). PEDV N protein was first truncated into 3 overlapping fragments, and a specific band was observed at PEDV N2 (aa 118–325) fragment (Fig. 4B). Subsequently, PEDV N2 fragment was truncated into 6 smaller segments, and PEDV N2-5 (aa 250–287) showed a strong reaction with mAb 8G2 (Fig. 4C). Next, 12-amino acid peptides covering PEDV N2-5 were expressed, and positive band appeared in PEDV N2-15-17 (aa 271–282) (Fig. 4D). To further pinpoint the epitope, the N-terminal domain (NTD) of PEDV N2-15-17 was truncated one by one in the fourth round. The results showed the minimal epitope recognized by mAb 8G2 was 274-DLKDIPEWR-282 (Fig. 4E). The contribution of each amino acid in the 274–282 epitope was also examined. After sequentially substituting with alanine, mAb 8G2 still reacted with mutants at positions 275 (L-A), 276 (K-A), 278 (I-A), and 280 (E-A), but not with mutants at 277 (D-A), 279 (P-A), and 281 (W-A). These results suggested that the key residues for 8G2 binding are 277-D, 279-P, and 281-W (Fig. 4F). Fig. 4Antigen epitope mapping of mAb 8G2. A Schematic diagram of PEDV N protein epitope mapping. B The full-length PEDV N protein was truncated into 3 segments: PEDV N1, N2 ,and N3. The reactivity of truncated PEDV N proteins with mAb 8G2 was analyzed by WB. C PEDV N2 fragment was further divided into PEDV N2-1, PEDV N2-2, PEDV N2-3, PEDV N2-4, PEDV N2-5, and PEDV N2-6. The expression and reactivity of these proteins were explored by SDS-PAGE and WB. D The fragment of PEDV N2-5 was further divided into 17 peptides. E The NTD of PEDV N2-5-17 fragment was sequentially truncated, and the reactivity with MAb-8G2 was evaluated. F The amino acid residue in the minimal epitope 274-DLKDIPEWR-282 of mAb 8G2 were replaced with alanine to identify key amino acids Antigen epitope mapping of mAb 8G2. A Schematic diagram of PEDV N protein epitope mapping. B The full-length PEDV N protein was truncated into 3 segments: PEDV N1, N2 ,and N3. The reactivity of truncated PEDV N proteins with mAb 8G2 was analyzed by WB. C PEDV N2 fragment was further divided into PEDV N2-1, PEDV N2-2, PEDV N2-3, PEDV N2-4, PEDV N2-5, and PEDV N2-6. The expression and reactivity of these proteins were explored by SDS-PAGE and WB. D The fragment of PEDV N2-5 was further divided into 17 peptides. E The NTD of PEDV N2-5-17 fragment was sequentially truncated, and the reactivity with MAb-8G2 was evaluated. F The amino acid residue in the minimal epitope 274-DLKDIPEWR-282 of mAb 8G2 were replaced with alanine to identify key amino acids Conservation of mAb 8G2 among various coronaviruses To evaluate the conservation of identified epitope, the sequences of PEDV and other coronaviruses N proteins were aligned by DNAMAN software. The amino acid sequences of most representative PEDV strains showed the epitope 274-DLKDIPEWR-282 is 100% conserved among different PEDV genogroups (including G1, G2, and S-Indel strains). In addition, 8 alpha, 8 beta, 3 gamma, and 4 delta coronaviruses were selected and compared. There was a low level of sequence homology at the corresponding epitope position among these other coronaviruses, ranging from 11.1% to 33.3% (Fig. 5B). These results demonstrated that the 8G2 epitope is conserved among different PEDV strains, making it a promising candidate for PEDV specific detection. Fig. 5Conservation analysis of identified epitope for mAb 8G2. Amino acid alignment of 274-DLKDIPEWR-282 among diverse PEDV strains (A) and other coronaviruses (B) were compared. Heat map of homology comparison between PEDV strain and other coronaviruses were analyzed Conservation analysis of identified epitope for mAb 8G2. Amino acid alignment of 274-DLKDIPEWR-282 among diverse PEDV strains (A) and other coronaviruses (B) were compared. Heat map of homology comparison between PEDV strain and other coronaviruses were analyzed The structure analysis of identified epitope To understand the epitope’s conformation recognized by mAb 8G2, DNASTAR was employed to predict the secondary structure of PEDV N protein. The epitope region was predicted to exhibit an α-helix, hydrophilicity, a antigenic index, and surface accessibility (Fig. 6A). Three-dimensional structural model further revealed 274-DLKDIPEWR-282 epitope is exposed on the surface of the PEDV N protein, forming a combination of random coil and α-helix structures (Fig.6B and 6C). This exposure likely contributes to the strong reactivity of mAb 8G2. Fig. 6Bioinformatic characteristics of identified epitope. A DNASTAR software was utilized to predict the second structural features of B-cell epitope. B and C The spatial localization of mAb 8G2 epitope on PEDV N protein was determined by AlphaFold 3 Bioinformatic characteristics of identified epitope. A DNASTAR software was utilized to predict the second structural features of B-cell epitope. B and C The spatial localization of mAb 8G2 epitope on PEDV N protein was determined by AlphaFold 3 Preliminary applications of mAb 8G2 against PEDV N protein To investigate the potential applications of mAb 8G2, Vero cells were infected with PEDV and collected at various time points. WB analysis showed N protein became detectable at 6 h post infection (hpi), increased at later time points, and reached its highest level at 36 hpi (Fig. 7A). Consistently, IFA and flow cytometry demonstrated the expression of PEDV N protein as early as 6 hpi, with levels increasing levels over time (Fig. 7B and C). IHC staining of tissues from infected piglets showed PEDV-positive signals in the jejunal of PEDV-infected piglets, while no positive cells were observed in TGEV or PDCoV, nor in uninfected control piglets (Fig. 7D). Meanwhile, the subcellular localization of N protein was also investigated. Vero cells were transfected with pCAGGS-HA-PEDV N along with ER, Golgi, mitochondria, lysosome, and peroxisome markers. As shown in Fig. 7E, N protein co-localized predominantly with ER, with a small fraction detected in mitochondria and lysosome. These results demonstrated mAb 8G2 can be used in other relevant research methods to detect PEDV. Fig. 7Preliminary applications of mAb 8G2. A, B, and C Kinetics of PEDV N protein expression in Vero cells, as detected by WB (A), flow cytometry (B), and IFA (C). D Distribution of PEDV in the jejunum of piglets. E Subcellular localization of PEDV N protein Preliminary applications of mAb 8G2. A, B, and C Kinetics of PEDV N protein expression in Vero cells, as detected by WB (A), flow cytometry (B), and IFA (C). D Distribution of PEDV in the jejunum of piglets. E Subcellular localization of PEDV N protein Discussion PEDV is one of the most devastating pathogens that causes serious global economic losses to the swine industry [16, 17]. Epidemiological studies showed that PEDV had the highest detection rate in pig diarrhea samples. During 2019–2020, 36.5% of monitored sites in the USA had at least one PEDV introduction [18]. The PEDV positivity rate in Vietnam was reported to range from 27% to 70% [19, 20]. According to data from China’s Ministry of Agriculture and Rural Affairs, PEDV was the primary pathogen responsible for the majority of piglet incident cases and deaths in 2024. Zhang et al. showed the PEDV infection rate remained constantly > 40% across 2011 to 2021 in seven provinces and Shanghai City of China [17]. Another study revealed PEDV sample prevalence rates of 47.40 to 52.22%, and farm-level prevalence at 76.06% between 2021 and 2023 in five southern provinces of China [21]. Furthermore, PEDV showed high mixed infection rate with other enteroviruses, which aggravates the severity of the disease [21–25]. Since these viruses display similar transmission routes, clinical symptoms, and pathological changes, there is an urgent need to develop discriminate diagnostic assays for PEDV. Antibodies to structural proteins in serum play an important role in the diagnosis of coronavirus infection. Antibody test data help monitor disease prevalence and evaluate the immune status of a population, thereby facilitating making reasonable and effective immunization schedule. The S glycoprotein on the surface of the virus plays a key role in eliciting virus neutralizing antibodies [26, 27]. However, S protein is highly variable and prone to mutation, which greatly reduce the accuracy of detection methods. In contrast, PEDV N protein is more conserved and stable than S protein. N protein is highly expressed, and antibody responses to N protein are abundant during the early stages of infection [28]. Accordingly, N protein based mAb detection methods have been widely applied in the coronavirus surveillance. More mAbs against PEDV N protein and their detailed epitopes are needed. In this study, three high-quality mAbs (8G2, 6F3, and 3E1) specific to PEDV N protein were successfully generated. The titers of these antibodies exceeded 1:102400, demonstrating their strong potential for diagnostic applications. Overlapping truncations of PEDV N protein showed the epitope of mAb 8G2 was 274-DLKDIPEWR-282, which was a novel B-cell epitope not reported in previous literature. To our knowledge, multiple antigenic epitopes of PEDV N protein have been identified previously, such as 12-KRVPLSLY-19, 133-EIVEPNTP-140, 155-GNNRSRSP-162, 235-IGENPDKL-242, 252-RSDSSGKNTPK-262, 302-KNFGDAEFV-310, 350-TYNYKMTV-357, 372DAFKTGNA380, 402-IYDDVGVP-409, and 413-THANLEWD-420 [14, 15]. Additionally, the conformational epitope of mAb PN-D4 (residues 18–133), which contains an intrinsically disordered protein, was identified. The mAbs and their corresponding epitopes, as reported by Wang et al., were specifically recognized by PEDV or PEDV antisera, highlighting their potential for use in developing an immunoassay. These epitopes deepen our understanding of PEDV N protein, and provide important tools for the establishment of detection methods and vaccine development. Although N protein has high expression level, cross-reactivity among different coronaviruses can make accurate diagnoses difficult. Hyperimmune TGEV antisera or TGEV N protein mAb showed one-way cross-react with PEDV or PEDV N protein. Two conserved regions (66-QIGYWN-71 and 92-FYYLGTGPH-100) shared between TGEV and PEDV may contribute to this cross-reaction [29]. Xie et al. found sequences 58-RWRMRRGERIE-68 and 78-LGTGPHAD-85 mediated two-way cross-reactivity between TGEV and PEDV [30]. PEDV have been shown to cross-react with PDCoV, and four regions (47-GYW-49, 67-FYYTGTGPRGNLKY-82,194-PKG-197, and 329-EWD-332) have been implicated [31]. Such cross-reactivity among coronaviruses might be attributed to highly conserved motif present in the NTD of N proteins. Thus, truncating the NTD can improve the specificity of the immunoassays targeting N protein [29]. The minimal epitopes of mAb 8G2 was located in the C-terminal domain (CTD) of N protein, not the NTD. Moreover, the epitope regions of 8G2 are highly conserved among G1a, G1b, G2a, and G2b PEDV strains. The corresponding sequence identity in other coronaviruses is only about 11.1%–33.3%, which is consistent with the lack of cross-reaction observed with TGEV and PDCoV. Our results suggested good epitope of mAb 8G2 is beneficial for PEDV specific diagnosis. N protein is composed of NTD, CTD, and an intrinsic disorder region (IDR) [32]. NTD is mainly responsible for binding to viral RNA, and CTD self-associates to form a stable nucleocapsid structure that maintains the stability of the viral genome [33, 34]. IDR mediates interactions between NTD and CTD, thereby enabling potential independent function of the two domains. Unique linear-α-helix complex conformation of mAb 8G2 may contribute to the protein’s stability. A series of experiments demonstrated 8G2 can be widely used in IFA, WB, IHC, and flow cytometry, suggesting it is an ideal tool to explore the function of N protein in viral life cycle, especially during the replication stage. The primary function of N protein is to encapsulate the viral RNA genome. Immunofluorescence analysis revealed a cytosolic signal for the N protein [35]. Scherer et al. further observed N protein is expressed first and accumulates around the folded ER membranes in convoluted layers [36]. Conserved N proteins exhibit similar patterns of subcellular localization and function across different coronavirus strains. The cellular distribution of N protein provides insights into the spatiotemporal dynamics of coronaviruses, contributing to a better understanding of their replication, transmission, and pathogenesis. Conclusions Three mAbs against PEDV N protein (8G2, 6F3, and 3E1) were successfully generated. The novel linear B-cell epitope of 8G2 (274-DLKDIPEWR-282) was identified, which was highly conserved among different PEDV strains and could be used as PEDV-specific diagnostic methods. Our findings are significant for investigating the structural and functional analysis of PEDV N protein, as well as for developing accurate clinical detection of PEDV. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4. Supplementary Material 5. Supplementary Material 5. Supplementary Material 6. Supplementary Material 6. Supplementary Material 7. Supplementary Material 7. Supplementary Material 8. Supplementary Material 8. Supplementary Material 9. Supplementary Material 9. Supplementary Material 10. Supplementary Material 10. Supplementary Material 11. Supplementary Material 11. Supplementary Material 12. Supplementary Material 12. Supplementary Material 13. Supplementary Material 13. Supplementary Material 14. Supplementary Material 14. Supplementary Material 15. Supplementary Material 15. Supplementary Material 16. Supplementary Material 16. Supplementary Material 17. Supplementary Material 17. Supplementary Material 18. Supplementary Material 18. Supplementary Material 19. Supplementary Material 19. Supplementary Material 20. Supplementary Material 20. Supplementary Material 21. Supplementary Material 21. Supplementary Material 22. Supplementary Material 22. Supplementary Material 23. Supplementary Material 23. Supplementary Material 24. Supplementary Material 24. Supplementary Material 25. Supplementary Material 25. Supplementary Material 26. Supplementary Material 26. Supplementary Material 27. Supplementary Material 27. Supplementary Material 28. Supplementary Material 28. Supplementary Material 29. Supplementary Material 29. Supplementary Material 30. Supplementary Material 30.